Cambrex Corporation says higher demand for APIs for controlled substances and branded drugs drove Q2 growth and confirms it is on the lookout for acquisitions.
Further evidence US diabetics pay more for drugs than sufferers in comparable countries has emerged this month in a study assessing the diseases’ economic impact.
After fending off hostile takeover bids from Valeant for nearly seven months, Allergan is finally agreeing to a takeover, but with Ireland-based Actavis.
Quintiles issued a mixed set of revised financial predictions for 2013, increasing its earnings per share forecast after a surge of new business wins and narrowing its service revenue.
Covance has reported a net loss of $12.7m in this year’s Q2 as what it says is the result of facility closures and restructuring costs, particularly for its early phase development section.
Sartorius Stedim Biotech (SSB) has revised its full year guidance after its range of single-use products drove revenue gains in the first half of 2011.
Tax benefit from the sale of its US Phase I business helped CRO Charles Rivers Laboratories (CRL) to grow profits in the first quarter despite falling revenues and low demand.
PPD and Charles River Laboratories (CRL) finished 2010 with very different quarters, each posting results that illustrate trends within the CRO sector.
Syringe maker Unilife said it was hit by falling revenues, costs of US relocation and workforce expansion in Q4, but that significant business progress was made in fiscal 2010.
Warnex says demand for contract analysis services increase in Q2 thanks to expansion in diagnostics market and forecasts growth opportunities in India.
Datatrak has posted an operating profit, grown revenues and recorded the forth consecutive quarter-on-quarter increase in backlog in its latest results.
Operating income at Kendle fell by 48 per cent in the first quarter, driven by a dip in net revenues, but the CRO is encouraged that improvements in April suggest the market is improving.
Phase Forward has adopted technologies from BMC Software to improve its operational efficiency, make “substantial cost savings” and ensure its systems maintain the availability, reliability and compliance demanded by clients.
Cardiology and eClinical specialist eResearch Technology missed analysts estimates of sales and earnings in the fourth quarter of 2008, but still posted a near-14 per cent increase in operating profit.
US-based biopharmaceutical product providers Millipore has met its
revenue and earnings target over the fiscal year, helped by its
Serologicals acquisition in the fourth quarter and a solid
performance by its main business driver:...
Sartorius has reported 7.6 per cent increase in sales revenue in
2006 rising to €520.1m ($677.4m), due to the biotechnology
division's decision to focus on disposable systems.
Cardinal Health reported a mixed bag of results in its fourth
quarter, with revenues rising well on the back of rising demand for
its pharmaceutical distribution services, although operating profit
fell 9 per cent, in line with forecasts,...
Manufacturing consolidation and acquisition costs helped reduce net
income as Millipore revealed its 2005 second quarter financial
results. The company has just completed the purchase of two
companies with the intention of increasing...
US biotechnology company Invitrogen reported record second-quarter
revenue but warned that top-line growth for the rest of 2004 would
be less than expected, citing an increasingly competitive business
environment.
Fisher Scientific, the US-based science and laboratory products
group, hinted earlier this week that it may be looking to make
another acquisition, despite its prediction of a period of
consolidation in the wake of its $714 million...
US packaging giant MeadWestvaco has reported a 38 per cent increase
in fourth-quarter profits, helped by cost-cutting, cash from the
sale of forest land and strong sales of consumer packaging
materials.
Chemicals major BASF managed to post a small gain in third quarter
revenues despite the difficult operating environment affecting the
industry; chairman Hambrecht points to early signs that the sector
may have hit bottom and be ready...
